You just read:

EPIX Therapeutics Announces Completion of DIAMOND-AF Paroxysmal Study and First Enrollment in DIAMOND-AF II Persistent Study

News provided by

EPIX Therapeutics, Inc.

04 Oct, 2018, 12:17 BST